Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide in Hyperinsulinemic Hypoglycemia
NCT03053284Phase 2Withdrawn
- Sponsor
- Montefiore Medical Center
- Start
- Apr 2017
- Primary completion
- Jan 2018
- Modality
- Peptides, Small Molecules
01
Overview
A Phase 2 trial of pasireotide LAR in congenital hyperinsulinism (HI), insulinoma, sponsored by Montefiore Medical Center. Planned start Apr 2017; status: withdrawn.
02
Drugs
pasireotide LAR
03
Conditions
congenital hyperinsulinism (HI)insulinoma
Beyond the preview
Go deeper on NCT03053284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053284.